Literature DB >> 21094951

Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.

Tulin Gokmen1, Omer Erdeve, Nahide Altug, Serife Suna Oguz, Nurdan Uras, Ugur Dilmen.   

Abstract

OBJECTIVE: To compare oral ibuprofen with intravenous ibuprofen for closure of patent ductus arteriosus in very low birth weight (VLBW) preterm infants. STUDY
DESIGN: In a prospective, randomized study, 102 VLBW preterm infants with patent ductus arteriosus received either intravenous or oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours. The success rate and evaluation of renal tolerance using cystatin-C were the major outcomes.
RESULTS: Patent ductus arteriosus closure rate was significantly higher with oral ibuprofen (84.6% versus 62%) after the first course of the treatment (P = .011). The cystatin-C level increased significantly after treatment in the oral group (P = .001), but did not change with intravenous ibuprofen (P = .4).
CONCLUSIONS: Oral ibuprofen is more effective than intravenous ibuprofen for ductal closure in VLBW infants. The increase in the cystatin-C level with oral treatment suggests that patients with borderline renal function should be evaluated and followed closely.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094951     DOI: 10.1016/j.jpeds.2010.10.008

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  26 in total

1.  Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

Authors:  Gozde Kanmaz; Omer Erdeve; Fuat Emre Canpolat; Serife Suna Oğuz; Nurdan Uras; Nahide Altug; Ben Greijdanus; Uğur Dilmen
Journal:  Eur J Clin Pharmacol       Date:  2012-11-06       Impact factor: 2.953

Review 2.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

Review 3.  Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

Authors:  Mehmet Yekta Oncel; Omer Erdeve
Journal:  World J Clin Pediatr       Date:  2016-02-08

4.  Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study.

Authors:  S Suna Oguz; H Gozde Kanmaz; Ugur Dilmen
Journal:  Int J Clin Pharm       Date:  2012-01-11

Review 5.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

6.  Relationship Between Hemodynamically Significant Ductus Arteriosus and Ischemia-Modified Albumin in Premature Infants.

Authors:  Hasan Kahveci; Cüneyt Tayman; Fuat Laloğlu; Nazan Kavas; Murat Ciftel; Osman Yılmaz; Esra Laloğlu; Abdulah Erdil; Hülya Aksoy; Salih Aydemir
Journal:  Indian J Clin Biochem       Date:  2015-09-15

Review 7.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

8.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

9.  Patent ductus arteriosus in premature neonates.

Authors:  Olachi J Mezu-Ndubuisi; Ghanshyam Agarwal; Aarti Raghavan; Jennifer T Pham; Kirsten H Ohler; Akhil Maheshwari
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

10.  Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation.

Authors:  Ozmert M A Ozdemir; Mustafa Doğan; Kazım Küçüktaşçı; Hacer Ergin; Ozlem Sahin
Journal:  Pediatr Cardiol       Date:  2013-08-13       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.